JDRF Blog
FDA Authorizes Tidepool Loop, an Automated Insulin Dosing App
The FDA authorized the Tidepool Loop, an algorithm that could be used to work with commercially available insulin pumps and continuous glucose monitors.
Read More About FDA Authorizes Tidepool Loop, an Automated Insulin Dosing App
FDA Approves Tzield™—A Watershed Moment for the T1D Community
JDRF celebrates the FDA approval of Tzield, the first disease-modifying therapy to delay clinical T1D in people at risk of developing the disease.
Read More About FDA Approves Tzield™—A Watershed Moment for the T1D Community
TypeOneNation Summits: All New for 2023
JDRF's 2023 TypeOneNation Summits have an exciting new approach to educate and inspire the type 1 diabetes (T1D) community.
Read More About TypeOneNation Summits: All New for 2023
What We Can Be Proud of in 2022
There is tremendous progress in accelerating cures, improving lives, and advocating for people with T1D and their loved ones over the past year.
Read More About What We Can Be Proud of in 2022Recent Articles
Sign up for our monthly Research Newsletter, The Pipeline, to stay up to date on the latest and greatest in T1D science.
By clicking Sign Up, I agree to the JDRF Privacy Policy. I also agree to receive emails from JDRF and I understand that I may opt out of JDRF subscriptions at any time.